Clinical Trial Update: Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating switching to Certican (everolimus) for Hepatitis C viremia in adult kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Kidney Transplantation

Drugs mentioned

• Certican (everolimus)

Snippet

Sponsor: Irmandade Santa Casa de Misericórdia de Porto Alegre | Conditions: Renal Allograft, Hepatitis C | Phase 4 | Status: COMPLETED